The International Adaptations of the NCCN Guidelines address the availability of resources, metabolic differences in populations, evidence-based regional practice patterns, and regulatory status of health care technologies used in cancer care in a specific country or region. These targeted regional resources are created to combat the rising cancer rates and unique care circumstances in different countries/regions. International Adaptations reflect both the recommendations as delineated in the NCCN Guidelines as well as locoregional variations in care contemplated by the local care environment. Additionally, they may represent both the optimal care that resource-constrained areas aspire to provide and pragmatic approaches that provide effective treatment options in the setting of resource constraints.
International Adaptations are developed by oncology thought leaders in the specific country or region in collaboration with NCCN Guidelines Panel Members to aid clinicians in determining the appropriate and effective care in the specific country or region. These International Adaptions have been used to support improved availability of effective treatment options in specific countries or regions. NCCN has collaborations with the oncologists/oncology organizations in the following countries/regions: Brazil, China, Middle East and North Africa (MENA), Poland, Spain, Sub-Saharan Africa (SSA), and Vietnam.
Recommendations within the guidelines are represented as follows:
Black Text: Recommendations that are widely applicable. |
Italicized Blue Text: Country/region-specific modifications that are appropriate and/or feasible. |
Gray Text: Recommendations that may be costly, technically challenging, and/or not widely available in the specific country/region.* |
Gray Text with |
Prostate Cancer Version 4.2024 (English)
Cervical Cancer Version 1.2023 (English)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (English)
Uterine Neoplasms Version 2.2023 (English)
Adult Cancer Pain Version 1.2025 (English)
B-Cell Lymphomas Version 1.2025 (English)
Breast Cancer Version 4.2025 (English)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 1.2025 (English)
Colon Cancer Version 1.2025 (English)
Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Version 2.2025 (English)
Hairy Cell Leukemia Version 1.2025 (English)
Hepatocellular Carcinoma Version 1.2025 (English)
Hodgkin Lymphoma Version 2.2025 (English)
Non-Small Cell Lung Cancer Version 3.2025 (English)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 1.2025 (English)
Prostate Cancer Version 1.2025 (English)
T-Cell Lymphomas Version 1.2025 (English)
Adolescent and Young Adult (AYA) Oncology Version 2.2025 (English)
Anal Carcinoma Version 1.2024 (English)
Breast Cancer Version 4.2024 (English)
Central Nervous System Cancers Version 2.2021 (English)
Cervical Cancer Version 1.2021 (English)
Colon Cancer Version 5.2024 (English)
Head and Neck Cancers Version 2.2025 (English)
Hodgkin Lymphoma Version 2.2025 (English)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 5.2022 (English)
Rectal Cancer Version 4.2024 (English)
Colon Cancer Version 5.2024 (English)
Acute Lymphoblastic Leukemia Version 2.2024
Acute Myeloid Leukemia Version 3.2024
Adolescent and Young Adult (AYA) Oncology Version 2.2024
Adult Cancer Pain Version 2.2021
Anal Carcinoma Version 2.2022
Antiemesis Version 2.2023
B-Cell Lymphomas Version 3.2024
Biliary Tract Cancers Version 3.2023
Bladder Cancer Version 1.2023
Bone Cancer Version 2.2022
Breast Cancer Version 3.2024
Breast Cancer Screening and Diagnosis Version 2.2024
Cancer in People with HIV Version 1.2024
Central Nervous System Cancers Version 2.2022
Cervical Cancer Version 1.2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 1.2025
Chronic Myeloid Leukemia Version 1.2025
Colon Cancer Version 2.2022
Colorectal Cancer Screening Version 3.2022
Esophageal and Esophagogastric Junction Cancers Version 3.2023
Gastric Cancer Version 2.2023
Gastrointestinal Stromal Tumors Version 2.2022
Gestational Trophoblastic Neoplasia Version 1.2023
Head and Neck Cancers Version 2.2023
Hematopoietic Growth Factors Version 1.2024
Hepatocellular Carcinoma Version 2.2023
Hodgkin Lymphoma Version 3.2024
Kaposi Sarcoma Version 1.2024
Kidney Cancer Version 4.2023
Mesothelioma: Pleural Version 1.2024
Multiple Myeloma Version 1.2025
Neuroendocrine and Adrenal Tumors Version 1.2022
Non-Small Cell Lung Cancer Version 4.2024
Occult Primary Version 2.2024
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023
Palliative Care Version 2.2021
Pancreatic Adenocarcinoma Version 2.2022
Pediatric Acute Lymphoblastic Leukemia Version 1.2025
Pediatric Aggressive Mature B-Cell Lymphomas Version 2.2024
Pediatric Central Nervous System Cancers Version 1.2024
Pediatric Hodgkin Lymphoma Version 1.2024
Penile Cancer Version 1.2023
Prevention and Treatment of Cancer-Related Infections Version 2.2023
Prostate Cancer Version 4.2024
Prostate Cancer Early Detection Version 2.2024
Rectal Cancer Version 3.2022
Small Cell Lung Cancer Version 2.2024
Smoking Cessation Version 2.2023
Soft Tissue Sarcoma Version 2.2022
Survivorship Version 1.2023
Testicular Cancer Version 1.2023
Thymomas and Thymic Carcinomas Version 1.2024
Thyroid Carcinoma Version 3.2022
Uterine Neoplasms Version 2.2023
Vulvar Cancer Version 1.2023
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2025
Non-Small Cell Lung Cancer Version 3.2023 (English)
Non-Small Cell Lung Cancer Version 3.2023 (Vietnamese)